Trial site
Prisma Health Cancer Institute
- 14running trials
- 8closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Conditions
- Colorectal cancer6 trials
- Lung cancer5 trials
- Liver and biliary tract cancer3 trials
- Acute myeloid leukaemia2 trials
- Childhood cancers2 trials
- Gastric and oesophageal cancer2 trials
- Kidney cancer2 trials
- Multiple myeloma2 trials
- Pancreatic cancer2 trials
- Prostate cancer2 trials
- Amyloidosis1 trial
- Bladder cancer1 trial
- and 8 more
- Phase
- Phase 17 trials
- Phase 27 trials
- Phase 36 trials
- Phase 1/21 trial
- Status
- Recruiting7 trials
- Active, not recruiting6 trials
- Terminated5 trials
- Completed3 trials
- Enrolling by invitation1 trial
- Lead sponsor
- Coherus Oncology, Inc.2 trials
- Aadi Bioscience, Inc.1 trial
- Actuate Therapeutics Inc.1 trial
- Asahi Kasei Therapeutics, Inc.1 trial
- Celgene1 trial
- and 16 more
Running trials
Recruiting
Recruiting
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Enrolling by invitation
Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies
Active, not recruiting
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer2 recruiting
- Prostate cancer2 recruiting
- Amyloidosis1 recruiting
- Childhood cancers1 recruiting
- Colorectal cancer1 recruiting
- Endometrial cancer1 recruiting
- Gastric and oesophageal cancer1 recruiting
- Kidney cancer1 recruiting
- Liver and biliary tract cancer1 recruiting
- Melanoma1 recruiting
- Neuroendocrine tumours1 recruiting
Closed trials
Terminated
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Terminated
Completed
Terminated
Completed
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Terminated
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Completed
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
Terminated
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Site data: ClinicalTrials.govUpdated 18 Nov 2026